AU2002321339B2 - New compounds, which are potent inhibitors of NA+/CA2+ exchange mechanism and are useful in the treatment of arrhythmias - Google Patents

New compounds, which are potent inhibitors of NA+/CA2+ exchange mechanism and are useful in the treatment of arrhythmias Download PDF

Info

Publication number
AU2002321339B2
AU2002321339B2 AU2002321339A AU2002321339A AU2002321339B2 AU 2002321339 B2 AU2002321339 B2 AU 2002321339B2 AU 2002321339 A AU2002321339 A AU 2002321339A AU 2002321339 A AU2002321339 A AU 2002321339A AU 2002321339 B2 AU2002321339 B2 AU 2002321339B2
Authority
AU
Australia
Prior art keywords
yloxy
chroman
phenylchroman
dmso
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002321339A
Other languages
English (en)
Other versions
AU2002321339A1 (en
Inventor
Arto Karjalainen
Tuula Koskelainen
Pekka Kotovuori
Pentti Nore
Leena Otsomaa
Sirpa Rasku
Jukka Tenhunen
Eija Tiainen
Olli Tormakangas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of AU2002321339A1 publication Critical patent/AU2002321339A1/en
Application granted granted Critical
Publication of AU2002321339B2 publication Critical patent/AU2002321339B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
AU2002321339A 2001-07-10 2002-07-10 New compounds, which are potent inhibitors of NA+/CA2+ exchange mechanism and are useful in the treatment of arrhythmias Ceased AU2002321339B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20011507A FI20011507A0 (fi) 2001-07-10 2001-07-10 Uusia yhdisteitä
FI20011507 2001-07-10
PCT/FI2002/000621 WO2003006452A1 (en) 2001-07-10 2002-07-10 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias

Publications (2)

Publication Number Publication Date
AU2002321339A1 AU2002321339A1 (en) 2003-05-22
AU2002321339B2 true AU2002321339B2 (en) 2007-06-21

Family

ID=8561628

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002321339A Ceased AU2002321339B2 (en) 2001-07-10 2002-07-10 New compounds, which are potent inhibitors of NA+/CA2+ exchange mechanism and are useful in the treatment of arrhythmias

Country Status (27)

Country Link
US (1) US7425568B2 (enExample)
EP (1) EP1412343B1 (enExample)
JP (1) JP4113839B2 (enExample)
KR (1) KR20040025697A (enExample)
CN (1) CN1281597C (enExample)
AR (1) AR036236A1 (enExample)
AT (1) ATE338038T1 (enExample)
AU (1) AU2002321339B2 (enExample)
BR (1) BR0211070A (enExample)
CA (1) CA2452918C (enExample)
DE (1) DE60214388T2 (enExample)
DK (1) DK1412343T3 (enExample)
EA (1) EA006580B1 (enExample)
ES (1) ES2269746T3 (enExample)
FI (1) FI20011507A0 (enExample)
HR (1) HRP20040133A2 (enExample)
HU (1) HUP0400391A3 (enExample)
IL (2) IL159647A0 (enExample)
MX (1) MXPA04000267A (enExample)
NO (1) NO20035821L (enExample)
NZ (1) NZ530490A (enExample)
PL (1) PL367958A1 (enExample)
PT (1) PT1412343E (enExample)
RS (1) RS50886B (enExample)
UA (1) UA76168C2 (enExample)
WO (1) WO2003006452A1 (enExample)
ZA (1) ZA200400145B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
AU2006222556B2 (en) 2005-03-11 2011-09-29 Armaron Bio Pty Ltd Flavonoid compounds and uses thereof
JP5941637B2 (ja) * 2011-09-12 2016-06-29 サノフイ 置換２−（クロマン−６−イルオキシ）−チアゾール及び医薬としてのその使用
SG11201400518RA (en) 2011-09-12 2014-04-28 Sanofi Sa Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
PL2567958T3 (pl) * 2011-09-12 2015-04-30 Sanofi Sa Podstawione 2-(chroman-6-yloksy)-tiazole i ich zastosowanie jako środków leczniczych
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
CN102993195B (zh) * 2011-09-14 2017-05-17 赛诺菲 取代的2‑(色满‑6‑基氧基)噻唑及其作为药物的用途
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
TWI633095B (zh) 2013-03-08 2018-08-21 賽諾菲公司 經取代－６－基氧基－環烷類及其作為醫藥品之用途
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
WO2019175464A1 (en) 2018-03-14 2019-09-19 Orion Corporation Compounds useful as inhibitors of sodium-calcium exchanger (ncx)
US11858930B2 (en) 2020-07-28 2024-01-02 Jazz Pharmaceuticals Ireland Limited Fused bicyclic RAF inhibitors and methods for use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) * 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
GB1068751A (en) * 1963-07-03 1967-05-10 Upjohn Co Phenolic cycloalkene derivatives
GB1154119A (en) * 1968-05-20 1969-06-04 Merck Ag E 3-Alkyl-Flavanones

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
FR2733685B1 (fr) * 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
JPH0967336A (ja) 1995-09-04 1997-03-11 Kanebo Ltd 新規なイソチオウレア誘導体
ES2191284T3 (es) 1997-03-27 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de 2-fenoxianilina.
JPH1149752A (ja) * 1997-08-05 1999-02-23 Taisho Pharmaceut Co Ltd フェノキシピリジン誘導体
DE19742508A1 (de) * 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
WO1999020598A1 (fr) * 1997-10-20 1999-04-29 Taisho Pharmaceutical Co., Ltd. Derives de la 2-phenoxyaniline
JPH11302235A (ja) 1998-04-15 1999-11-02 Taisho Pharmaceut Co Ltd フェノキシアルキルアミン誘導体
JP2002542291A (ja) * 1999-04-23 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー ジ環式アシルグアニジン・ナトリウム／プロトン交換抑制剤および方法
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) * 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
GB1068751A (en) * 1963-07-03 1967-05-10 Upjohn Co Phenolic cycloalkene derivatives
GB1154119A (en) * 1968-05-20 1969-06-04 Merck Ag E 3-Alkyl-Flavanones

Also Published As

Publication number Publication date
BR0211070A (pt) 2004-06-15
US7425568B2 (en) 2008-09-16
DK1412343T3 (da) 2007-01-02
PL367958A1 (en) 2005-03-07
RS50886B (sr) 2010-08-31
EP1412343A1 (en) 2004-04-28
WO2003006452A1 (en) 2003-01-23
IL159647A0 (en) 2004-06-01
NO20035821L (no) 2004-02-24
HUP0400391A2 (hu) 2004-12-28
DE60214388T2 (de) 2007-09-13
KR20040025697A (ko) 2004-03-24
ATE338038T1 (de) 2006-09-15
AR036236A1 (es) 2004-08-25
DE60214388D1 (de) 2006-10-12
UA76168C2 (en) 2006-07-17
EA200400161A1 (ru) 2004-06-24
EA006580B1 (ru) 2006-02-24
ES2269746T3 (es) 2007-04-01
ZA200400145B (en) 2005-04-08
HUP0400391A3 (en) 2008-03-28
EP1412343B1 (en) 2006-08-30
HK1068611A1 (en) 2005-04-29
PT1412343E (pt) 2006-12-29
JP4113839B2 (ja) 2008-07-09
HRP20040133A2 (en) 2004-08-31
CA2452918A1 (en) 2003-01-23
US20040235905A1 (en) 2004-11-25
CA2452918C (en) 2010-02-16
CN1525966A (zh) 2004-09-01
MXPA04000267A (es) 2004-07-23
FI20011507A0 (fi) 2001-07-10
CN1281597C (zh) 2006-10-25
IL159647A (en) 2008-04-13
RS604A (sr) 2006-12-15
NZ530490A (en) 2005-12-23
JP2005504738A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
CA2452918C (en) New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias
CA1210770A (en) Leukotriene antagonists
AU2002321339A1 (en) New compounds, which are potent inhibitors of NA+/CA2+ exchange mechanism and are useful in the treatment of arrhythmias
PT699185E (pt) Derivados de guanidina inibidores da permuta na+/h+ nas celulas
AU2004203943B2 (en) Pyridine derivatives useful for inhibiting sodium/calcium exchange system
WO2012068284A2 (en) Efficient method for preparing functionalized benzosuberenes
CA1273349A (en) Leukotriene antagonists
NZ323521A (en) Compounds for treating reversible obstructive airway disease or allergic conditions
CA2330576A1 (en) Substituted benzazocines as nicotine-binding inhibitors
ES2251827T3 (es) Derivado de piridina y producto farmaceutico que lo contiene.
DE19831878A1 (de) Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69217717T2 (de) Benzopyranderivate und Verfahren zu deren Herstellung
US5356915A (en) Tetralones with pharmacological activity, compositions containing them
CA2617703A1 (en) Androgen modulators
DE3302814A1 (de) Neue allylamine, verfahren zu ihrer herstellung und ihre verwendung
NZ228716A (en) Chromene derivatives and pharmaceutical compositions
KR930006777B1 (ko) 피리도[1,2-a]인돌 화합물 및 그 제조방법
CH637939A5 (de) Pyridin-3-ole.
EP0294615A1 (en) Cyclobutene-3,4-dione-intermediates and their use in the preparation of histamine h2-antagonists
WO1998015524A1 (en) Improved process for the synthesis of beta-ketonitriles
IE66342B1 (en) Process for the preparation of (3-fluoropyridin-2-yloxy)-phenoxypropionic acids
DK151962B (da) Analogifremgangsmaade til fremstilling af (e)-2-((amino)arylmethylen)-benzo(b)thiophen-3(2h)-oner
Metz et al. Cloxacepride and related compounds: A new series of orally active antiallergic compounds
MXPA00009342A (en) Pyridine derivative and pharmaceutical containing the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired